Vanguard Group Inc Cytokinetics Inc Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 11,983,838 shares of CYTK stock, worth $592 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,983,838
Previous 11,849,547
1.13%
Holding current value
$592 Million
Previous $476 Million
16.86%
% of portfolio
0.01%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding CYTK
# of Institutions
369Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$870 Million0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$725 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$387 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$315 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.65MShares$180 Million4.28% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.65B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...